



EVER Pharma UK Ltd  
Bloxham Mill  
Barford Road  
Bloxham  
Oxfordshire  
OX15 4FF

## **EVER Pharma UK Ltd: Transparency Disclosure Methodological Notes for Reporting Year 2024**

EVER Pharma UK Ltd was incorporated in the UK in May 2018. The company is a wholly owned subsidiary of EVER Holdings GmbH, a pharmaceutical company with Headquarters in Austria.

UK healthcare professionals, who have received Transfer of Value (ToV), whether engaged with EVER Pharma UK Ltd or the parent company EVER Holdings GmbH will be captured in this disclosure submission.

EVER Pharma UK Ltd has not considered any Transfer of Value that may have occurred between non-UK Healthcare Professionals and EVER Holdings GmbH, in other markets outside the UK.

With regards to the specific categories for disclosing transfer of value, we confirm that all 2024 sponsorship, fees and relevant transfer of value is in line with our current UK SOPs.

### **Definitions**

#### **Transfer of Value (ToV)**

The term Transfer of Value means a direct or indirect ToV, whether in cash, in kind or otherwise, made for promotional purposes or otherwise, in connection with the sale or development of licensed medicines.

#### **Healthcare Professional (HCP)**

HCP's include members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their activities may administer, prescribe, purchase, recommend or supply a medicine.

#### **Healthcare Organisation (HCO)**

HCO means either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more HCPs or other relevant decision makers provide services.

#### **Other Relevant Decision Maker (ORDM)**

ORDMs particularly include those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not HCPs.

## **Transfers of Value**

Categories disclosed against individual HCPs or ORDMs for ToV made in 2024

- 1) Fees for service and consultancy and associated related expenses agreed in the fee for service/consultancy contract EVER Pharma UK Ltd pays fair market value fees for the provision of services provided by HCPs/ORDMs.
- 2) Associated expenses. These may include: travel expenses, accommodation rates (which may include dinner, bed and breakfast, or room only rates) and other associated expenses claimed by the service provider (e.g. parking, any additional appropriate subsistence).
- 3) Payments made to consultants in relation to market research where the identity of the participants is known to EVER Pharma UK Ltd. During 2024, EVER Pharma UK Ltd did not make any such ToVs for market research.

Categories disclosed against individual HCOs for ToV made in 2024

- 1) Sponsorship agreements with HCOs/third parties appointed by HCOs to manage an event, such as part funded independent education events. When sponsorship also included catering costs and any other forms of funding (e.g., logistical costs) as part of a sponsorship package these are disclosed as a ToV (sponsorship).

## **Individual**

All individuals disclosed in this submission, have provided their authorisation to share their transfer of value, by signing a formal UK contract between EVER Pharma UK Ltd and the relevant UK HCP.

Each HCP/ORDM is entitled to withdraw their consent to disclosure at any time. In such cases, HCPs and ORDMs are asked to send an email to [info.uk@everpharma.com](mailto:info.uk@everpharma.com), notifying the company that they wish to withdraw their consent for the current calendar reporting period. Following publication of EVER Pharma UK Ltd ToV data, HCPs and ORDMs are also able to contact the ABPI to withdraw their consent.

## **EVER Pharma Nurse Service**

EVER Pharma provides a nurse service as part of the purchase price of its product, this service being provided by an external agency.

The total cost of providing this service to the NHS has been calculated using the total external agency costs for the provision of nurses, divided by the number of NHS Trusts where a contract was in place to deliver nurse support in 2024. Hence, this provides an average cost per Trust.

The cost is then disclosed against each NHS trust as a 'sponsorship agreement with HCOs/Third party organisations appointed by HCOs to manage an event' as this TOV cannot easily be disclosed elsewhere on the template.

## **Finance**

### **VAT:**

No HCP contracted or receiving transfer of value in this period has indicated that they are VAT registered, therefore in this submission VAT has not been applied.

**Tax:**

All HCPs have received indicated transfer of value, with the understanding those HCPs will manage any due taxation themselves.

**Healthcare Professionals Addresses**

HCPs workplace addresses have been provided by the healthcare professional prior to signing their contract.

**Timing**

EVER Pharma UK Ltd discloses to the ABPI all ToV made between January 1<sup>st</sup> and December 31<sup>st</sup> of 2024 by the date specified by the ABPI in the following year.

**Multiyear Contracts**

EVER Pharma UK Ltd did not have any multiyear contracts in 2024 relating to ToV.

A handwritten signature in black ink, appearing to read 'Derek Gallacher', with a large, stylized flourish at the end.

Derek Gallacher

Director

EVER Pharma UK Ltd

27<sup>th</sup> March 2025